Shanghai, China
Nutshell Therapeutics, founded in 2013, is a pioneering clinical stage biotech company headquartered in China. The company operates at the intersection of health care and cutting-edge technology, with a focus on developing allosteric small molecule therapies aimed at tackling undruggable or challenging biological targets. Their unique approach combines AI-based computational techniques with traditional web lab drug discovery methods.
Their slogan, "Deciphering Undruggable by Allostery", highlights their mission to transform difficult therapeutic challenges into actionable solutions. This innovative strategy has garnered significant interest from investors, culminating in a $40.00M Series A investment on 14 March 2022. The funding round was supported by prominent investors including Northern Light Venture Capital, Source Code Capital, Matrix Partners China, GenesisCapital, Kunlun Capital, Hengxu Capital, and Tencent. These investments underscore the confidence in the company's potential to revolutionize drug discovery and development.
